Preclinical studies have shown that treatment with the HDAC inhibitor vorinostat augmented the activity of the mTOR inhibitor temsirolimus to induce apoptosis in xenografted ccRCC cell lines through suppression of survivin levels (Mahalingam et al., 2010). This evidence concerns the gene HDAC9 and nonpapillary renal cell carcinoma.